Bundibugyo Ebolavirus 2026: Cross-Border Outbreak in DRC and Uganda
Latest official figures, geographic spread, response measures, and research developments in the 2026 Bundibugyo virus disease outbreak in DRC and Uganda.
Current Situation
The 2026 outbreak of Ebola disease caused by Bundibugyo virus was declared by the Democratic Republic of the Congo (DRC) on 15 May 2026 after national laboratory confirmation. WHO determined on 17 May that the event met the criteria for a Public Health Emergency of International Concern (PHEIC).
The latest official figures used by EbolaMap are for 24 August 2026:
| Location | Confirmed cases | Deaths | Status |
|---|---|---|---|
| DRC | 5,656 | 2,715 | Active transmission |
| Uganda | 20 | 2 | Outbreak ended 28 July |
| Total | 5,676 | 2,717 | 47.9% combined CFR |
The DRC outbreak has reached 58 of 151 health zones in six provinces: Ituri, North Kivu, South Kivu, Haut-Uele, Tshopo, and Bas-Uele. WHO describes it as the largest Ebola outbreak recorded in the DRC and the second largest globally. The epidemic remains active and is not yet under control.
What Is Bundibugyo Virus?
Bundibugyo virus (BDBV) belongs to the Orthoebolavirus genus. It was first identified during the 2007 outbreak in Bundibugyo District, Uganda, which caused 149 cases and 37 deaths. A second outbreak occurred in Isiro, DRC, in 2012, with 36 cases and 13 deaths.
Historically, Bundibugyo outbreaks had lower case-fatality ratios than many outbreaks caused by Zaire ebolavirus. The 2026 epidemic has been more severe: the DRC’s crude CFR was approximately 48.0% in data through 24 August.
| Feature | Bundibugyo virus | Zaire ebolavirus |
|---|---|---|
| Approved vaccine | None | Ervebo |
| Approved virus-specific treatment | None | Inmazeb and Ebanga |
| Previous recognized outbreaks | Uganda 2007; DRC 2012 | Multiple outbreaks since 1976 |
Supportive care—including fluid and electrolyte replacement, treatment of secondary infections, and organ support—therefore remains central to clinical management.
Geographic Spread and Response
Transmission has been concentrated in eastern and northeastern DRC. By 24 August, Ituri had reported 4,716 cases and 2,119 deaths, while North Kivu had reported 735 cases and 501 deaths. Haut-Uele reported 184 cases and 85 deaths; smaller totals were recorded in Tshopo, South Kivu, and Bas-Uele.
Uganda recorded 20 cases and two deaths. Its outbreak was declared over on 28 July 2026 after the required follow-up period without a new confirmed case. Continued cross-border surveillance remains important because communities, trade routes, and family networks connect affected areas in the DRC with neighboring countries.
ECDC’s 26 August update, based on country data through 24 August, reported:
- 792 patients hospitalized in isolation in the DRC
- 1,245 people recovered
- 80.9% of identified contacts under follow-up
- no secondary transmission linked to cases diagnosed outside Africa
WHO convened the second meeting of the IHR Emergency Committee on 18 August and published updated temporary recommendations on 24 August. The recommendations expand guidance for surveillance, infection prevention, clinical care, safe burials, community engagement, domestic mobility, mass gatherings, logistics, and border health. WHO recommends exit screening and cross-border information sharing, but not blanket flight suspensions or denial of entry to travellers from affected states.
Vaccines and Treatment Research
There is still no approved Bundibugyo-specific vaccine or antiviral treatment, but research has advanced during this outbreak:
- Two Bundibugyo-specific vaccine candidates have entered human trials.
- A third vaccine candidate that showed cross-protection in animal studies is moving toward a phase 3 trial.
- The International Coordinating Group allocated 70,000 Ervebo doses to DRC: 20,000 for a phase 3 trial and 50,000 for frontline and health workers. Ervebo is licensed for Zaire ebolavirus; whether it protects people against Bundibugyo virus is not yet known.
- The WHO-sponsored PARTNERS treatment trial has enrolled 100 patients.
These are research programs, not approved countermeasures. Claims about protection or treatment effectiveness should wait for trial results and regulatory review.
What to Watch Next
The most important indicators are new health zones or provinces reporting cases, the share of contacts successfully followed, delays between symptom onset and isolation, healthcare-worker infections, and whether treatment capacity keeps pace with admissions.
EbolaMap updates the outbreak timeline, interactive map, and news feed when new official situation reports are published.
Last updated 27 August 2026. Epidemiological data through 24 August 2026. Sources: WHO Regional Office for Africa Situation Report 15, ECDC’s 26 August epidemiological update, WHO’s 24 August IHR temporary recommendations, and the WHO/Africa CDC vaccine-allocation notice. DRC totals remain subject to review and harmonisation.
Sources & editorial review
Page updated August 27, 2026
- ECDC — Ebola outbreak in DRC and Uganda
- WHO AFRO — Bundibugyo virus disease Situation Report 15 (data through 23 August 2026)
- WHO — Updated IHR temporary recommendations (24 August 2026)
- WHO and Africa CDC — Allocation of 70,000 Ervebo doses to DRC (20 August 2026)
- WHO — Ebola virus disease fact sheet
Editorial verification: claims are checked against the cited public sources by the EbolaMap Editorial Team. This is not licensed-clinician review and the article is not medical advice. See our Editorial Policy and Corrections Policy.